Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.

Skip to Content

Patient Management Strategies for Newly Diagnosed CLL 

Published Date: April 15, 2025

Patient Management Strategies for Newly Diagnosed CLL

As the most prevalent type of leukemia that continues to have an increasing global incidence, chronic lymphocytic leukemia (CLL) represents a hematologic malignancy that most oncology health care providers will encounter.1 Appropriate choice of treatment coupled with multidisciplinary supportive and survivorship care are critical to optimizing outcomes for patients with CLL. To better understand the CLL treatment paradigm through the perspective of recognized thought leaders, NCODA members were invited to participate in a survey to obtain their insights into CLL management, including a focus on identifying patients with early signs of resistance or intolerance to current first-line treatments and exploring alternative agents within the same drug class.

A total of 97 NCODA members completed the survey. Responses were anonymously collected, and findings were aggregated into the data reported herein.

Read Report